Onconetix (ONCO) Halted, News Pending Feb 12, 2026 07:59AM
Onconetix (ONCO) files for 29.78M share offering by selling stockholders Dec 22, 2025 06:06AM
Onconetix (ONCO) files for 5.1M share offering by selling stockholders Oct 16, 2025 06:07AM
Onconetix and Ocuvex terminate merger agreement mutually Sep 26, 2025 08:25AM
Onconetix subsidiary licenses manufacturing IP to Immunovia for cancer test Sep 22, 2025 08:00AM


Jul 16, 2025 08:17AM Onconetix to acquire Ocuvex Therapeutics in stock deal
Jun 16, 2025 08:22AM Onconetix (ONCO) Announces Positive Decision by Nasdaq Hearings Panel
Jun 11, 2025 11:30AM Onconetix (ONCO) Announces 1:85 Reverse Share Split
May 22, 2025 04:51PM Onconetix (ONCO) receives additional notice from Nadaq regarding late 10-Q
Apr 8, 2025 08:32AM Onconetix (ONCO) signs loi for potential merger with Ocuvex Therapeutics
Apr 8, 2025 08:30AM Onconetix (ONCO) Signs LoI to Merge with Ocuvex Therapeutics
Apr 3, 2025 04:27PM Onconetix (ONCO) Announces Chairman Resignation
Mar 24, 2025 08:46AM Onconetix (ONCO) Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
Jan 27, 2025 06:19AM Onconetix (ONCO) Files for 50M Share Offering by Selling Stockholders
Dec 12, 2024 05:00PM Onconetix (ONCO) Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing
Nov 12, 2024 01:51PM Onconetix (ONCO) Files for 6.25M Share Offering by Selling Stockholders
Oct 3, 2024 09:07AM Onconetix (ONCO) Announces $2M Financing, $25M Equity Line of Credit
Jul 11, 2024 08:17AM Onconetix (ONCO) Receives $1.11M From Warrant Exercise